In this week’s issue:
- Juvenile Diabetes Research Foundation – Diabetes Type 1 Combination Therapy Research
- Terry Fox Research Institute – New Frontiers Program Project Grants
- Alex’s Lemonade Stand – 2014 Psychosocial Grants
- BrightFocus Foundation – Macular Degeneration Research
- Mitacs – Elevate Postdoctoral Fellowship
- Uniting Against Lung Cancer – Legacy Program
EOI Deadline: June 20, 2014
The Juvenile Diabetes Research Foundation, the world’s leading nonprofit organization with the mission to cure type 1 diabetes, is inviting expressions of interest for the clinical evaluation of combination therapies to address the disease.
Grants of up to $4.5 million over three years will be awarded for clinical trials designed to assess the safety, efficacy, and potential synergies of combination therapies targeting multiple facets of both new onset and established T1D. Possible research objectives include but are not limited to the employment of combinations utilizing immunomodulators (including antigen specific immunotherapies), beta cell antigen-specific therapies, enhancers of beta cell mass/function, reducers of beta cell stress and/or inflammatory pathways, metabolic control agents, and other relevant therapeutics to prevent or reverse T1D; the demonstration of safety, biologic effect, and potential efficacy of combinations in T1D; and comparative analyses of the risk-benefit ratio of the proposed combination versus the single agent.
For complete program guidelines and application procedures, visit the JDRF website.
LOI Deadline: July 2, 2014
The Terry Fox Research Institute (TFRI) is pleased to inform the scientific community regarding The 2015 Terry Fox New Frontiers PPG competition. This opportunity targets the aggregation of independently fundable research projects around a common theme, and the inclusion of core technologies that are used by each of the projects. It provides support to a group of researchers conducting independent high-quality investigations in a complex area of cancer research. The purpose is to stimulate group interaction based on the premise that high impact work in complex areas of cancer research requires collaboration. The Terry Fox New Frontiers Program Project Grant is designed for researchers with complementary skills, who investigate different aspects of a given cancer relevant topic, the results of which will be realized more rapidly and efficiently than if the individual projects were to be funded as a series of independent operating grants. This long-standing funding opportunity has supported many of the best cancer research groups in Canada.
The Request for Applications and competition documents, including key dates, may be downloaded from: http://tfri.ca/en/research/program-project-grants/program-project-grants-2015.aspx
LOI Deadline: July 18, 2014
The Alex’s Lemonade Stand Foundation is accepting Letters of Intent for two categories of grants through its Psychosocial Grant program.
1) Psychosocial Launch Grants are designed for early career researchers within seven years of receiving their terminal degree. Grants of up to $100,000 over two years will be awarded in support of studies that aim to explain and/or improve psychosocial outcomes of individuals affected by childhood cancer.
2) Psychosocial Family Impact Grants are designed for established investigators. Grants of up to $300,000 over three years will be awarded in support of studies that aim to explain and/or improve psychosocial outcomes of those affected by childhood cancer. Grants are designed to fund researchers with novel approaches to understanding the psychosocial aspects of pediatric cancer and whose proposals will have clinically significant impact.
The foundation will only consider LOIs from United States or Canadian nonprofit institutions. However, the principal investigator need not be a U.S. citizen.
For complete program guidelines and application instructions, visit the ALSF website.
LOI Deadline: July 31, 2014
The BrightFocus Foundation is currently accepting proposals to the Macular Degeneration Research program. Full applications are to be submitted by invitation only and are due November 18, 2014.
Applicants must first submit a Letter of Intent, which is due July 31, 2014. BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of age-related macular degeneration.
The maximum award value is US $80,000, per year, payable over two years (total value $160,000). All submitted proposals are subjected to peer-review by a qualified Scientific Review Committee, consisting of active academic and clinical researchers from within the macular degeneration research field.
Preference is made for exciting pilot projects that would not, at their present stage, be competitive for large government or industry awards. Typically these awards are made to junior investigators, or to more established investigators who are proposing particularly innovative research.
For application instructions and information about our programs, please visit the BrightFocus Foundation website at http://www.brightfocus.org/research/apply/main.html.
LOI Deadline: August 6, 2014, 5pm PST
Mitacs Elevate supports postdoctoral fellows and Canadian companies and partners to collaborate on cutting-edge research projects and build capacity for the next generation of R&D management leaders. Highlights of this program include:
- Two-year fellowship valued at $115,000 (plus $15,000 non-cash value in training)
- Customized training in professional and R&D management skills
- Long-term research project with a private-sector partner
- Open to all disciplines
Deadline: August 13, 2014
Uniting Against Lung Cancer, a nonprofit organization dedicated to providing funding for innovative research, has issued a Request for Proposals for its Legacy Program, the goal of which is to fund lung cancer research that can improve treatment and lead to a cure. In 2013, UALC awarded more than $1.5 million in research grants and expects to increase its support for research in 2014.
The program prioritizes novel ideas with the potential to make a significant impact on current treatment of lung cancer and patient survival, and places a high priority on funding research that demonstrates a clear path to improving patient care. Cross-disciplinary collaborations are strongly encouraged.
Areas of interest include but are not limited to developing novel therapies with the potential to cure lung cancers, genetic subsets of lung cancer/personalized medicine, primary and secondary drug sensitivity/resistance, lung cancer in never-smokers, improving outcomes in early-stage disease, and small-cell lung cancer.
Awards will range up to $100,000, to be paid over two years.
Investigators at all levels are encouraged to apply. While collaborations with industry partners are strongly encouraged, the principal investigator must be an academic researcher.
Please visit the UALC website for application details.